Tekton Research LLC
11/03/2026 | Press release | Archived content
FDA Approves ILUMYA for Adults With Active Psoriatic Arthritis
The U.S. Food and Drug Administration (FDA) has approved ILUMYA (tildrakizumab-asmn) for adults with active psoriatic arthritis. Paul Pickrell, MD, and our Austin, TX, team supported INSPIRE 1, one of the Phase 3 studies supporting the approval. Congratulations to Dr. Pickrell and our Austin team, and thank you to the participants who make this research possible!
Tekton Research LLC published this content on November 03, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 11, 2026 at 11:54 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]